The Middle East and Africa peripheral liquid embolic agents market size was valued at USD 19.5 million in 2025 and is projected to grow from USD 21.3 million in 2026 to USD 49.6 million by 2036, at a CAGR of 8.8% from 2026 to 2036. The market is driven by the rising prevalence of peripheral vascular disorders, increasing adoption of minimally invasive endovascular procedures, and growing use of embolization techniques in interventional oncology.
Increasing diagnosis and treatment of venous disorders is driving the use of peripheral liquid embolic agents across the Middle East, particularly for patients requiring minimally invasive endovascular procedures. Varicose veins account for a substantial proportion of venous disease cases, with factors such as aging, obesity, prolonged standing, physical inactivity, pregnancy, and chronic venous insufficiency contributing to the need for clinical intervention.
For instance, a study published by the MDPI in 2025, titled "Prevalence of Varicose Veins Among Teaching Professionals and Their Impact on Quality of Life and Job Performance." A cross-sectional study was conducted employing a stratified convenience sampling strategy among 400 school and university educators across different regions of Saudi Arabia. Data collection took place over four months, from mid-January to the end of April 2025.
In addition, expansion of healthcare infrastructure and investment in interventional facilities: The expansion of healthcare infrastructure across the Middle East is supporting the adoption of advanced minimally invasive and image-guided procedures, including embolization interventions. For instance, in February 2026, Aster DM Healthcare announced a Dh1 billion investment in the UAE to expand its healthcare network, including the development of two new hospitals, capacity expansion at an existing facility, and the introduction of advanced medical services. The investment is expected to add approximately 372 beds and create more than 1,000 jobs over the next two to three years. Such investments are strengthening the region's hospital capacity and improving access to specialized and technology-intensive healthcare services. The expansion of advanced clinical infrastructure is expected to increase the availability of facilities capable of performing complex catheter-based and image-guided interventions, thereby creating opportunities for greater adoption of peripheral liquid embolic agents in the UAE and wider Middle East market.
Increasing diagnosis and treatment of venous disorders is driving the use of peripheral liquid embolic agents across the Middle East, particularly for patients requiring minimally invasive endovascular procedures. Varicose veins account for a substantial proportion of venous disease cases, with factors such as aging, obesity, prolonged standing, physical inactivity, pregnancy, and chronic venous insufficiency contributing to the need for clinical intervention.
For instance, a study published by the MDPI in 2025, titled "Prevalence of Varicose Veins Among Teaching Professionals and Their Impact on Quality of Life and Job Performance." A cross-sectional study was conducted employing a stratified convenience sampling strategy among 400 school and university educators across different regions of Saudi Arabia. Data collection took place over four months, from mid-January to the end of April 2025.
In addition, expansion of healthcare infrastructure and investment in interventional facilities: The expansion of healthcare infrastructure across the Middle East is supporting the adoption of advanced minimally invasive and image-guided procedures, including embolization interventions. For instance, in February 2026, Aster DM Healthcare announced a Dh1 billion investment in the UAE to expand its healthcare network, including the development of two new hospitals, capacity expansion at an existing facility, and the introduction of advanced medical services. The investment is expected to add approximately 372 beds and create more than 1,000 jobs over the next two to three years. Such investments are strengthening the region's hospital capacity and improving access to specialized and technology-intensive healthcare services. The expansion of advanced clinical infrastructure is expected to increase the availability of facilities capable of performing complex catheter-based and image-guided interventions, thereby creating opportunities for greater adoption of peripheral liquid embolic agents in the UAE and wider Middle East market.
Middle East and Africa Peripheral Liquid Embolic Agents Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, the analyst has segmented the Middle East and Africa peripheral liquid embolic agents market report based on product, application and end use:Product Outlook (Revenue, USD Million, 2021 - 2036)
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates/tissue glues combined
- n-butyl cyanoacrylate (n-BCA)
- n-hexyl cyanoacrylate (n-HCA)
Application Outlook (Revenue, USD Million, 2021 - 2036)
- Peripheral Vascular Hemorrhage
- Hypervascular Tumors
- Peripheral Vascular Malformations/AVMs
- Aneurysms/Pseudoaneurysms
- Type II Endoleaks
- Portal Vein Embolization (PVE)
- Venous Applications (varicocele, PCS, varicose veins)
End Use Outlook (Revenue, USD Million, 2021 - 2036)
- Hospitals
- Others
Country Outlook (Revenue, USD Million, 2021-2036)
- Middle East
- North Africa
- South Africa
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East and Africa Peripheral Liquid Embolic Agents Market Variables, Trends, & Scope
Chapter 4. Middle East and Africa Peripheral Liquid Embolic Agents Market: Product Estimates & Trend Analysis
Chapter 5. Middle East and Africa Peripheral Liquid Embolic Agents Market: Application Estimates & Trend Analysis
Chapter 6. Middle East and Africa Peripheral Liquid Embolic Agents Market: End Use Estimates & Trend Analysis
Chapter 7. Middle East and Africa Peripheral Liquid Embolic Agents Market: Regional Estimates & Trend Analysis by Product, Application, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic
- GEM S.r.l. (H.B. Fuller Company)
- BALT Group (via Compass Medical Pty Ltd)
